Systemic inflammation and cardiac surgery: an update

Perfusion (United Kingdom) - Tập 16 Số 5 - Trang 353-360 - 2001
George Asimakopoulos1
1Specialist Registrar in Cardiothoracic Surgery, Cardiothoracic Department, Imperial College School of Medicine at Hammersmith Hospital, Du Cane Road, London,

Tóm tắt

Cardiac surgery with cardiopulmonary bypass (CPB) is associated with the development of a systemic inflammatory response that can often lead to dysfunction of major organs. The systemic inflammation can be assessed intra- and postoperatively by measuring concentrations of inflammatory mediators in plasma and tissues. These concentrations, however, do not always correlate with the degree of observed organ dysfunction. Various strategies have been used to reduce inflammatory phenomena in patients undergoing CPB. Cardiac surgery without CPB has been performed increasingly with satisfactory results over the past few years. Attenuation of systemic inflammation and improved outcome in high risk patients are potential benefits of this technique. The emergence and expanding performance of cardiac surgical procedures without the use of CPB has given us an excellent tool to investigate the relative importance of CPB as a cause of systemic inflammation. Aprotinin is a protease inhibitor which is used in cardiac surgical patients for its haemostatic effects. Aprotinin has anti-inflammatory properties, the nature of which have not been completely clarified. This article presents a summary of the published literature investigating inflammatory response and organ dysfunction in patients who have cardiac surgery without CPB. It also presents an overview of recent data on the anti-inflammatory action mechanisms of aprotinin.

Từ khóa


Tài liệu tham khảo

10.1097/00003246-199206000-00025

10.1177/026765919901400406

10.1177/026765919901400405

10.1016/S0003-4975(99)00781-X

10.1177/026765919601100305

10.1097/00003246-199703000-00009

10.1001/archsurg.1993.01420160028003

10.1016/0003-4975(95)00840-3

10.1016/S1010-7940(00)00553-4

10.1016/S0003-4975(00)01152-8

10.1016/S0003-4975(97)01127-2

10.1378/chest.113.5.1290

10.1016/S0003-4975(00)01177-2

10.1016/S0003-4975(00)02325-0

10.1016/S0022-5223(99)70426-5

10.1016/S0003-4975(00)01419-3

10.1016/S0003-4975(00)02205-0

10.1016/S1010-7940(99)00072-X

10.1016/S0022-5223(97)70208-3

10.1016/S1010-7940(00)00420-6

10.1016/S1010-7940(99)00234-1

10.1136/hrt.81.5.495

Wildhirst SM, 2000, Eur J Med Res, 5, 222

Brown PM, 1999, Circulation, 100, II125

10.1016/S0003-4975(99)01196-0

10.1016/S0003-4975(00)02250-5

10.1016/S0003-4975(99)01574-X

10.1016/S0003-4975(00)01843-9

10.1016/S0003-4975(99)00318-5

10.1016/S1053-0770(99)90123-4

10.1378/chest.119.1.25

10.1016/S0003-4975(98)00830-3

10.1016/S0022-5223(99)70177-7

10.1016/S0003-4975(99)00566-4

10.1016/S0140-6736(87)91190-1

Taylor KM., 1993, Anticoagulation, hemostasis, and blood preservation in cardiovascular surgery, 132

10.1016/S0022-5223(95)70027-7

10.1213/00000539-199610000-00006

10.1016/S0003-4975(99)01553-2

Jandl JH., 1996, Blood: textbook of hematology, 2, 615

10.1056/NEJM199607043350108

10.1056/NEJM198902093200606

10.1161/01.CIR.92.8.2276

10.1016/0003-4975(94)90380-8

10.1067/mtc.2000.106323

10.1177/026765910001500604

Asimakopoulos G, Effects of aprotinin on endothelial activation. J Thorac Cardiovasc Surg

10.1016/S0003-4975(98)00181-7

De Paulis R, 1999, G Ital Cardiol, 29, 375

Diegeler A, 2000, Circulation, 102, III95

10.1055/s-2007-1010209

10.1016/S0003-4975(99)01420-4

10.1055/s-2000-8352

10.1016/S0003-4975(99)00729-8

10.1016/S0003-4975(99)00315-X

Thông tin
Thông tin xuất bản

Perfusion (United Kingdom)

Tập 16 Số 5

353-360

Thông tin tác giả